Sign Up For Free » Here's a closer look at three discounted S&P 500 dividend stocks you can feel good about buying and ...
Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma ...
The new formulation of Keytruda, currently under FDA review, is sparking conflict with Halozyme, which makes enzymes that ...
Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback